Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2020 16:00 ET | Source: RadioMedix Inc.

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada

Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of...
January 03, 2020 00:00 ET | Source: RadioMedix Inc.

RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
January 22, 2019 10:00 ET | Source: RadioMedix Inc.

RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.

Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
January 09, 2019 01:00 ET | Source: RadioMedix Inc.

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
November 13, 2018 10:00 ET | Source: RadioMedix Inc.

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors

Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
August 26, 2018 21:00 ET | Source: Curium

Curium and RadioMedix Announce Exclusive Global Agreement for 64Cu-Dotatate Development

St. Louis and Houston, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission...
January 10, 2018 05:00 ET | Source: RadioMedix Inc.

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
June 22, 2017 16:00 ET | Source: RadioMedix Inc.

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
February 06, 2017 06:00 ET | Source: RadioMedix Inc.

First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

Houston, TX; Los Angeles, CA, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging...
November 01, 2016 01:00 ET | Source: RadioMedix Inc.

RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right